Sodium–glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant benefits beyond glucose-lowering effects and are widely endorsed in clinical guidelines for patients with heart failure (HF), chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), demonstrating reductions in the risk of hospitalization for heart failure (HF) and cardiovascular (CV) death, particularly in patients with established atherosclerotic cardiovascular disease [1,2,3,4,5,6,7,8]. This evidence concerns the gene SLC5A2 and chronic kidney disease.